Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

David Hoffmanna Early Stage Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany;b In Silico Team, Boehringer Ingelheim, Biberach/Riss, GermanyView further author information

Joschka Bauera Early Stage Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany;b In Silico Team, Boehringer Ingelheim, Biberach/Riss, GermanyView further author information

Markus Kossnerc Scientific Services, Chemical Computing Group, Cologne, GermanyView further author information

Andrew Henryd Scientific Support, Chemical Computing Group, Cambridge, UKView further author information

Anne R. Karow-Zwicka Early Stage Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany;b In Silico Team, Boehringer Ingelheim, Biberach/Riss, GermanyView further author information

Giuseppe Licaria Early Stage Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany;b In Silico Team, Boehringer Ingelheim, Biberach/Riss, GermanyCorrespondence[email protected]

https://orcid.org/0000-0002-8490-7536 View further author information

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

Supporting_Information_revision.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

Supporting_Information_revision.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date